Home | History | Fund Raising | Events | Volunteers | Medical Research | Media | XLP Stories | Contact us | Useful Links | Literature
|
The XLP Research Trusts core objective is to fund the highest quality international research into the cause, inheritance, diagnosis, treatment and management of XLP and to develop a cure for this primary immunodeficiency. 2010/11 Grant awards The XLP Research Trust is now seeking innovative scientific and clinical research projects to fund from across the world. Basic Grant Awards (<£40,000 or <$59,000 or <€48,000) are offered to support short-term, small-scale pilot or proof of concept research projects that may lead to new avenues of investigation and understanding of XLP. Ph.D. studentships are also available to exceptional candidates in laboratories with a proven track record of research in XLP or similar immunodeficiencies. Applicants are invited to submit Preliminary Applications by the 20th August 2010. Please download the following four files:
You must return
Preliminary applications are assessed by members of our Medical Panel and Trustees. Full grant applications are subject to full peer review by at least two independent external referees and our Medical Panel. The decision to approve a grant is made by the Trustees on the recommendations of our Medical Panel. Medical research into XLP is still very much in its infancy but we do ensure that the money you donated is only spent on the very ‘best science’. Every application received in fully peer reviewed by external experts who pass on their advice to our board of trustees. This trustees then decides which projects would give the best scientific outcomes for XLP and the best value for money. Equally importantly, we demand absolute clarity regarding how grants are spent, and monitor and evaluate carefully. The external experts decide on which projects offer the best scientific outcomes for XLP and the best value for money. Based on their opinion the trustees then decide which projects to fund. Equally importantly, we demand absolute clarity regarding how grant monies will be spent, and have in place monitoring systems that will enable us to evaluate carefully the progress of the research work undertaken will your valuable donations. You can download a copy of our medical research strategy from here.
There is also a glossary of medical terms, related to XLP, available here. The charity made its first awards in the summer of 2007. Current Projects ”Regulation of NKT cell development and function by SAS, the protein defective in X-linked lymphoproliferative disease” Kim Nichols, MD Children’s Hospital of Philadelphia, United States of America. £72,550 Awarded over two years, June 2008 - June 2010. Abstract Our laboratory is studying proteins that regulate the activity of T lymphocytes, white blood cells that are essential in the immune response against specific pathogens, such as viruses. By identifying molecules that control host protective mechanisms, we hope to develop improved therapies for patients suffering from severe virus infections and virus-associated cancers. We have made progress by studying X-linked lymphoproliferative disease (XLP), a rare and often fatal immunodeficiency characterized by a decreased ability to control Epstein-Barr virus infection, a reduced production of specialized proteins known as antibodies and an increased risk to develop lymphoma. Previously, we identified SHZDlA, the gene that is abnormal in XLP patients. SHZDlA encodes for a protein known as SAP, which regulates the functions of T lymphocytes. Recently, we observed that SAP is required for the development of a potent but poorly understood subset of T lymphocytes known as natural killer T (IVKT) cells. Currently, our research is focused on understanding how SAP controls NKT cell development and establishing whether this adaptor regulates mature NKT cell functions. We are also examining how the absence of IVKT cells contributes to the abnormal antiviral immune responses that occur in XLP patients and SAP-deficient mice. These studies will increase our understanding of NKT cell biology and may provide insights into how LIKT cells can be expanded and activated to enhance host immunity.
“Characterising the Phenotype, Specificity and Function of Virus-Specific CD8+ T cells in SAP-deficient XLP patients” Dr Stuart Tangye and Dr Umamainthan Palendira Abstract X-linked lymphoproliferative disease (XLP) is an inherited disease. The gene defect results in the absence of a protein that is involved in signalling through numerous receptors on the surface of white blood cells. These receptors may be crucial for the function of cytotoxic T lymphocytes, a population of white blood cells that are important for anti-viral immune responses and for tumour clearance. One major problem for XLP patients is their increased sensitivity to infection with Epstein Barr Virus (EBV), a virus which causes asymptomatic infection in the majority of the population, but can occasionally cause self-limiting infectious mononucleosis (Glandular fever). Exposure to EBV is often fatal in XLP patients and even those who survive acute virus infection often go on to develop further complications such as lymphoma, a cancer of immune cells. We aim to investigate why XLP patients are particularly susceptible to infection with EBV. We will achieve this by characterising the differences in the function of cytotoxic white blood cells collected from XLP patients and from healthy individuals. We will also determine why XLP patients are able to respond to common viruses such as Influenza virus. This study will provide a greater understanding of why XLP patients are particularly susceptible to one particular virus, which causes widespread tissue damage of often death in these patients. The findings from this study may aid in the development of new treatmentsltherapies for XLP patients.
“Molecular characterization of XLP-like diseases” Sylvain Latour, Christelle Lenoir and Stéphanie Rigaud Abstract The X-linked lymphoproliferative syndrome (XLP) or Purtilo syndrome is a rare inherited immunodeficiency that is characterized by an inappropriate immune response to Epstein-Barr virus (EBV) infection. Mutations in the genes SAP and XIAP underlie most of the patients with familial XLP disease. We have recently established that both XIAP and SAP deficiency lead to a specific defect in a particular lymphocyte subpopulation, the NKT lymphocytes. The aim of this proposal is : There is a significant number of patients presenting an EBV-associated lymphoproliferative syndrome (diagnosed as an XLP-like disease) that are not carrying mutations in SAP nor XIAP. In these patients, the genetic origin of the condition is unknown suggesting that other genes may account for the pathology in these patients. The identification of the gene defect (s) that cause these related syndromes will be undertaken. This study will help identify people who may suffer from XLP-like conditions. |
Johnathan McIntyre My name is Tabatha Marshall from Hinesville, Georgia. I am the mother of a 15-year-old XLP child. He is the only living one in my family that has t...  more
|
Download: Medical Research Notes for Applicants 
Important Note: The information contained in this site is intended only as a guideline, not as a substitute for medical advice. Always consult your doctor first.